SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jack Doerr who wrote (396)3/1/2000 8:20:00 PM
From: LemurHouse  Read Replies (1) of 656
 
Nuvance -- for asthma -- will be an even bigger block-buster than Enbrel if approved. Imnx is presenting info on all three opportunities (Enbrel for CHF and Psoriatic arthritis, plus nuvance) within the next several days, and that is calling more attention to the stock. Nuvance is nearing the end of phase II trials, if I'm not mistaken.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News